A photo of Margaret Collins.

Staff Pathologist, Division of Pathology

Director, GI Pathology

Professor, UC Department of Pathology and Laboratory MedicineUC Department of Pediatrics

513-636-4261

513-636-3924

Board Certified

My Biography & Research

Biography

I belong to a community of researchers at Cincinnati Children’s Hospital Medical Center, plus other institutions here and abroad, who are unwaveringly committed to finding cures for pediatric gastrointestinal (GI) diseases, including eosinophilic gastrointestinal disorders (EGID). This is especially important to me after meeting patients and their caregivers, witnessing the impact that EGID has on their lives and sharing their hope for a Food and Drug Administration (FDA)-approved therapy.

My research strives to improve diagnostic methods for children with GI diseases, such as EGID and inflammatory bowel disease. As a pediatric pathologist at Cincinnati Children’s, I help evaluate the efficacy of various therapies, including biologics, for pediatric patients who have EGID. I also participate in multi-institutional studies of pediatric inflammatory bowel disease.

I helped create the eosinophilic esophagitis histology scoring system (EoEHSS), which systematically evaluates esophageal biopsies obtained for eosinophilic esophagitis, the most common form of EGID. Some of the features evaluated correlate with symptoms and potentially provide new therapeutic endpoints.

Beginning in 2011, U.S. News & World Report named me one of the Top Doctors in Pathology. In 2020, I received the American Academy of Asthma, Allergy and Immunology (AAAAI) and American Partnership for Eosinophilic Disorders (APFED) award for the best EGID abstract at the AAAAI annual meeting.

Clinical Interests

Pediatric gastrointestinal pathology; eosinophilic gastrointestinal diseases; biopsy analyses; primary study endpoints; novel therapies to treat eosinophilic esophagitis in children; disorders of bowel immunity; bowel motility disorders

Academic Affiliation

Professor, UC Department of Pathology and Laboratory MedicineUC Department of Pediatrics

Clinical Divisions

Colorectal Disorders, Pathology, Eosinophilic Disorders

Research Divisions

Pathology, Eosinophilic Disorders

My Education

BS: Fordham University, NY, 1972.

MD: Georgetown University, Washington, D.C., 1977.

Residency: Pathology, New York Hospital, NY, 1977-80; Pathology, Columbia-Presbyterian Medical Center, NY, 1980-83.

Fellowship: Research, New York Lung Association, Columbia-Presbyterian Medical Center, N.Y., 1983-85; Research, American Lung Association, Columbia-Presbyterian Medical Center, NY, 1985-87.

Certification: Pathology, 1981; Pediatric Pathology, 1991.

My Publications

Selected Publication

Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. Hirano, I; Dellon, ES; Hamilton, JD; Collins, MH; Peterson, K; Chehade, M; Schoepfer, AM; Safroneeva, E; Rothenberg, ME; Falk, GW; et al. Gastroenterology. 2020; 158:111-122.e10.

Maintaining outstanding outcomes using response- And biology-based therapy for intermediate-risk neuroblastoma: A report from the children’s oncology group study ANBL0531. Twist, CJ; Schmidt, ML; Naranjo, A; London, WB; Tenney, SC; Marachelian, A; Shimada, H; Collins, MH; Esiashvili, N; Adkins, ES; et al. Journal of Clinical Oncology. 2019; 37:3243-3255.

Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses from a 12-Week, Phase 2, Randomized, Placebo-controlled Trial. Collins, MH; Dellon, ES; Katzka, DA; Hirano, I; Williams, J; Lan, L. American Journal of Surgical Pathology. 2019; 43:1501-1509.

Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Hyams, JS; Thomas, SD; Gotman, N; Haberman, Y; Karns, R; Schirmer, M; Mo, A; Mack, DR; Boyle, B; Griffiths, AM; et al. The Lancet. 2019; 393:1708-1720.

Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration Why Was the Consortium of Eosinophilic Gastrointestinal Disease Researchers Established?. Gupta, SK; Falk, GW; Aceves, SS; Chehade, M; Collins, MH; Dellon, ES; Gonsalves, N; Hirano, I; Mukkuda, VA; Peterson, KA; et al. Gastroenterology. 2019; 156:838-842.

Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis. Dellon, ES; Katzka, DA; Collins, MH; Gupta, SK; Lan, L; Williams, J; Hirano, I. Clinical Gastroenterology and Hepatology. 2019; 17:666-673.e8.

RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Hirano, I; Collins, MH; Assouline-Dayan, Y; Evans, L; Gupta, S; Schoepfer, AM; Straumann, A; Safroneeva, E; Grimm, M; Smith, H; et al. Gastroenterology. 2019; 156:592-603.e10.

Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Dellon, ES; Liacouras, CA; Molina-Infante, J; Furuta, GT; Spergel, JM; Zevit, N; Spechler, SJ; Attwood, SE; Straumann, A; Aceves, SS; et al. Gastroenterology. 2018; 155:1022-1033.e10.

Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. Aceves, SS; King, E; Collins, MH; Yang, G; Capocelli, KE; Abonia, JP; Atkins, D; Bonis, PA; Carpenter, CL; Dellon, ES; et al. Journal of Allergy and Clinical Immunology. 2018; 142:130-138.e1.

Eosinophilic Gastrointestinal Disorders Pathology. Collins, MH; Capocelli, K; Yang, G. Frontiers in Medicine. 2018; 4.